Physician profile
Titilola Temitope Sode
NPI 1003203381
$11,287.63
in general payments reported to CMS, 2019-2025
29 companies · $2,197 in 2025
The $2,197 reported for 2025 was more than what 86% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $133 · 2021: $774 · 2022: $2,556 · 2023: $1,959 · 2024: $3,668 · 2025: $2,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,460 · Education: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,459.59 |
| Education | $364.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,615.14 | 2020-2025 | Skyrizi, Rinvoq, Humira |
| Pfizer INC. | $947.57 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $745.18 | 2023-2025 | Zoryve |
| Allergan, INC. | $698.15 | 2022 | |
| Lilly USA, LLC | $617.11 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $609.61 | 2021-2024 | |
| Janssen Biotech, INC. | $602.48 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $597.01 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $593.70 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $569.25 | 2020-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $357.38 | 2022-2025 | Ilumya |
| Dermavant Sciences, INC. | $313.44 | 2022-2024 | Vtama |
| Organon LLC | $297.97 | 2025 | Vtama, Nexplanon |
| Amgen INC. | $281.48 | 2021-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $244.90 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $220.85 | 2021-2025 | Nemluvio, Epsolay, Aklief |
| Ucb, INC. | $204.33 | 2021-2025 | Bimzelx |
| Incyte Corporation | $189.52 | 2022-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $148.62 | 2022 | |
| Almirall LLC | $100.76 | 2022-2025 | Seysara, Klisyri |
| Merz North America, INC. | $94.30 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $59.53 | 2024-2025 | Jublia, Duobrii, Targretin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.24 | 2022-2024 | Spevigo |
| Botanix Sb INC | $35.26 | 2025 | Sofdra |
| Springworks Therapeutics, INC. | $27.56 | 2025 | Gomekli |
| Vyne Pharmaceuticals INC. | $22.70 | 2021 | |
| Krystal Biotech INC | $21.52 | 2025 | Vyjuvek |
| Mayne Pharma Commercial LLC | $19.12 | 2022 | |
| Verrica Pharmaceuticals INC. | $16.95 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Titilola Sode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.